|作者：||Su Qiang, Zhang Xiao-Chen, Zhang Chen-Guang, Hou Yan-Li, Yao Yu-Xia, Cao Bang-Wei|
1Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
2Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China.
3Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.
4Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
5Department of Digestive Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
|刊名：||Journal of immunology research, 2018, Vol.2018 , pp.1027323|
|原始语种摘要：||We performed a systematic review and meta-analysis to determine the risk of immune-related pancreatitis associated with the treatment by immune checkpoint inhibitors (ICIs) for solid tumors. Eligible studies were selected from multiple databases including phase II/III randomized controlled trials (RCTs) with ICIs in solid tumor patients. The data were analyzed with Stata version 12.0 software. After excluding ineligible studies, a total of 15 clinical trials were considered eligible for the meta-analysis, which included 9099 patients. Compared with chemotherapy or placebo, the risk ratio (RR) for all-grade lipase elevation after CTLA-4 inhibitor treatment was 1.05 (95% confidence interval (CI): 1.01-2.24, p = 0.047). However, the risk for pancreatitis after ICI treatment in any subgroup... was not significantly higher than that after control therapy. In addition, compared with ipilimumab/nivolumab alone, the RR for all-grade and high-grade lipase elevation under combination treatment of nivolumab and ipilimumab was 6.43 (95% CI: 1.43-28.99, p = 0.015) and 6.44 (95% CI: 1.39-29.79, p = 0.017), respectively, and the RR for all-grade amylase elevation under combination treatment was 6.08 (95% CI: 1.51-24.44, p = 0.011). Our meta-analysis has demonstrated that both CTLA-4 inhibitors alone and combination treatment of nivolumab and ipilimumab could increase the risk of amylase or lipase elevation, but not significantly increase the risk of pancreatitis when compared with controls.|